Diabetic Gastroparesis Yields to Blockade of This Receptor

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.

The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.

Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.